Polaryx Therapeutics (PLYX) Competitors

$4.54 -0.58 (-11.33%)

Closing price 04:00 PM Eastern

Extended Trading

$4.64 +0.10 (+2.20%)

As of 05:42 PM Eastern

PLYX vs. MRVI, LBRX, DRUG, SDGR, and TBPH

Should you be buying Polaryx Therapeutics stock or one of its competitors? The main competitors of Polaryx Therapeutics include Maravai LifeSciences (MRVI), LB Pharmaceuticals (LBRX), Bright Minds Biosciences (DRUG), Schrodinger (SDGR), and Theravance Biopharma (TBPH). These companies are all part of the "pharmaceutical products" industry.

How does Polaryx Therapeutics compare to Maravai LifeSciences?

Maravai LifeSciences (NASDAQ:MRVI) and Polaryx Therapeutics (NASDAQ:PLYX) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment.

: Maravai LifeSciences currently has a consensus target price of $5.38, indicating a potential upside of 39.61%. Polaryx Therapeutics has a consensus target price of $10.00, indicating a potential upside of 120.26%. Given Polaryx Therapeutics' higher probable upside, analysts plainly believe Polaryx Therapeutics is more favorable than Maravai LifeSciences.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Maravai LifeSciences
1 Sell rating(s)
1 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.40
Polaryx Therapeutics
1 Sell rating(s)

0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: In the previous week, Maravai LifeSciences had 5 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 6 mentions for Maravai LifeSciences and 1 mentions for Polaryx Therapeutics. Maravai LifeSciences' average media sentiment score of 0.57 beat Polaryx Therapeutics' score of 0.00 indicating that Maravai LifeSciences is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Maravai LifeSciences
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Polaryx Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: 50.3% of Maravai LifeSciences shares are owned by institutional investors. 2.5% of Maravai LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
: Polaryx Therapeutics has lower revenue, but higher earnings than Maravai LifeSciences.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Maravai LifeSciences $185.74M 5.33 -$130.77M -$0.90 N/A
Polaryx Therapeutics N/A N/A N/A N/A N/A
: Polaryx Therapeutics has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -70.40%. Polaryx Therapeutics' return on equity of 0.00% beat Maravai LifeSciences' return on equity.
Company Net Margins Return on Equity Return on Assets
Maravai LifeSciences -70.40% -22.79% -11.82%
Polaryx Therapeutics N/A N/A N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Polaryx Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maravai LifeSciences	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Polaryx Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maravai LifeSciences	$185.74M	5.33	-$130.77M	-$0.90	N/A
Polaryx Therapeutics	N/A	N/A	N/A	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-70.40%	-22.79%	-11.82%
Polaryx Therapeutics	N/A	N/A	N/A

Summary

Maravai LifeSciences beats Polaryx Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Polaryx Therapeutics compare to LB Pharmaceuticals?

Polaryx Therapeutics (NASDAQ:PLYX) and LB Pharmaceuticals (NASDAQ:LBRX) are both small-cap manufacturing companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and media sentiment.

: Polaryx Therapeutics currently has a consensus target price of $10.00, indicating a potential upside of 120.26%. LB Pharmaceuticals has a consensus target price of $37.20, indicating a potential upside of 13.14%. Given Polaryx Therapeutics' higher possible upside, analysts plainly believe Polaryx Therapeutics is more favorable than LB Pharmaceuticals.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Polaryx Therapeutics
1 Sell rating(s)
0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
LB Pharmaceuticals
1 Sell rating(s)

1 Hold rating(s)

4 Buy rating(s)

2 Strong Buy rating(s)
2.88
: In the previous week, LB Pharmaceuticals had 12 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 13 mentions for LB Pharmaceuticals and 1 mentions for Polaryx Therapeutics. LB Pharmaceuticals' average media sentiment score of 1.09 beat Polaryx Therapeutics' score of 0.00 indicating that LB Pharmaceuticals is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Polaryx Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
LB Pharmaceuticals
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Polaryx Therapeutics N/A N/A N/A N/A N/A
LB Pharmaceuticals N/A N/A -$25.20M -$1.06 N/A
: Company Net Margins Return on Equity Return on Assets
Polaryx Therapeutics N/A N/A N/A
LB Pharmaceuticals N/A N/A N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polaryx Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Polaryx Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
LB Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polaryx Therapeutics	N/A	N/A	N/A	N/A	N/A
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$1.06	N/A

Company	Net Margins	Return on Equity	Return on Assets
Polaryx Therapeutics	N/A	N/A	N/A
LB Pharmaceuticals	N/A	N/A	N/A

Summary

LB Pharmaceuticals beats Polaryx Therapeutics on 5 of the 6 factors compared between the two stocks.

How does Polaryx Therapeutics compare to Bright Minds Biosciences?

Polaryx Therapeutics (NASDAQ:PLYX) and Bright Minds Biosciences (NASDAQ:DRUG) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends, media sentiment and valuation.

: Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Polaryx Therapeutics N/A N/A N/A N/A N/A
Bright Minds Biosciences N/A N/A -$8.74M -$1.93 N/A
: In the previous week, Bright Minds Biosciences had 3 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 4 mentions for Bright Minds Biosciences and 1 mentions for Polaryx Therapeutics. Bright Minds Biosciences' average media sentiment score of 0.85 beat Polaryx Therapeutics' score of 0.00 indicating that Bright Minds Biosciences is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Polaryx Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Bright Minds Biosciences
3 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Polaryx Therapeutics currently has a consensus target price of $10.00, indicating a potential upside of 120.26%. Bright Minds Biosciences has a consensus target price of $128.60, indicating a potential upside of 49.15%. Given Polaryx Therapeutics' higher probable upside, equities research analysts clearly believe Polaryx Therapeutics is more favorable than Bright Minds Biosciences.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Polaryx Therapeutics
1 Sell rating(s)
0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
Bright Minds Biosciences
0 Sell rating(s)

1 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
2.86
: Polaryx Therapeutics' return on equity of 0.00% beat Bright Minds Biosciences' return on equity.
Company Net Margins Return on Equity Return on Assets
Polaryx Therapeutics N/A N/A N/A
Bright Minds Biosciences N/A -28.62% -28.08%
: 40.5% of Bright Minds Biosciences shares are owned by institutional investors. 42.7% of Bright Minds Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polaryx Therapeutics	N/A	N/A	N/A	N/A	N/A
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$1.93	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Polaryx Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bright Minds Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polaryx Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Bright Minds Biosciences	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

Company	Net Margins	Return on Equity	Return on Assets
Polaryx Therapeutics	N/A	N/A	N/A
Bright Minds Biosciences	N/A	-28.62%	-28.08%

Summary

Bright Minds Biosciences beats Polaryx Therapeutics on 6 of the 9 factors compared between the two stocks.

How does Polaryx Therapeutics compare to Schrodinger?

Schrodinger (NASDAQ:SDGR) and Polaryx Therapeutics (NASDAQ:PLYX) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

: Polaryx Therapeutics has lower revenue, but higher earnings than Schrodinger.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Schrodinger $255.87M 3.71 -$103.26M -$1.42 N/A
Polaryx Therapeutics N/A N/A N/A N/A N/A
: In the previous week, Schrodinger had 3 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 4 mentions for Schrodinger and 1 mentions for Polaryx Therapeutics. Schrodinger's average media sentiment score of 0.34 beat Polaryx Therapeutics' score of 0.00 indicating that Schrodinger is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Schrodinger
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Polaryx Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Schrodinger presently has a consensus target price of $20.50, indicating a potential upside of 59.29%. Polaryx Therapeutics has a consensus target price of $10.00, indicating a potential upside of 120.26%. Given Polaryx Therapeutics' higher possible upside, analysts plainly believe Polaryx Therapeutics is more favorable than Schrodinger.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Schrodinger
1 Sell rating(s)
4 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.33
Polaryx Therapeutics
1 Sell rating(s)

0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: Polaryx Therapeutics has a net margin of 0.00% compared to Schrodinger's net margin of -40.37%. Polaryx Therapeutics' return on equity of 0.00% beat Schrodinger's return on equity.
Company Net Margins Return on Equity Return on Assets
Schrodinger -40.37% -29.47% -14.69%
Polaryx Therapeutics N/A N/A N/A
: 79.1% of Schrodinger shares are held by institutional investors. 21.0% of Schrodinger shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Schrodinger	$255.87M	3.71	-$103.26M	-$1.42	N/A
Polaryx Therapeutics	N/A	N/A	N/A	N/A	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Schrodinger	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Polaryx Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Schrodinger	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Polaryx Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Net Margins	Return on Equity	Return on Assets
Schrodinger	-40.37%	-29.47%	-14.69%
Polaryx Therapeutics	N/A	N/A	N/A

Summary

Schrodinger beats Polaryx Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Polaryx Therapeutics compare to Theravance Biopharma?

Theravance Biopharma (NASDAQ:TBPH) and Polaryx Therapeutics (NASDAQ:PLYX) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

: Theravance Biopharma has higher revenue and earnings than Polaryx Therapeutics.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Theravance Biopharma $107.46M 8.02 $105.89M $2.03 8.24
Polaryx Therapeutics N/A N/A N/A N/A N/A
: In the previous week, Theravance Biopharma had 1 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 2 mentions for Theravance Biopharma and 1 mentions for Polaryx Therapeutics. Polaryx Therapeutics' average media sentiment score of 0.00 beat Theravance Biopharma's score of -0.09 indicating that Polaryx Therapeutics is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Theravance Biopharma
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Polaryx Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: 99.1% of Theravance Biopharma shares are held by institutional investors. 6.9% of Theravance Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
: Theravance Biopharma presently has a consensus target price of $21.83, indicating a potential upside of 30.50%. Polaryx Therapeutics has a consensus target price of $10.00, indicating a potential upside of 120.26%. Given Polaryx Therapeutics' higher possible upside, analysts clearly believe Polaryx Therapeutics is more favorable than Theravance Biopharma.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Theravance Biopharma
0 Sell rating(s)
4 Hold rating(s)

2 Buy rating(s)

2 Strong Buy rating(s)
2.75
Polaryx Therapeutics
1 Sell rating(s)

0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: Theravance Biopharma has a net margin of 98.54% compared to Polaryx Therapeutics' net margin of 0.00%. Theravance Biopharma's return on equity of 16.76% beat Polaryx Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Theravance Biopharma 98.54% 16.76% 9.23%
Polaryx Therapeutics N/A N/A N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Theravance Biopharma	$107.46M	8.02	$105.89M	$2.03	8.24
Polaryx Therapeutics	N/A	N/A	N/A	N/A	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Theravance Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Polaryx Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Theravance Biopharma	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.75
Polaryx Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Net Margins	Return on Equity	Return on Assets
Theravance Biopharma	98.54%	16.76%	9.23%
Polaryx Therapeutics	N/A	N/A	N/A

Summary

Theravance Biopharma beats Polaryx Therapeutics on 10 of the 12 factors compared between the two stocks.

Get Polaryx Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLYX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PLYX vs. The Competition

Export

Metric	Polaryx Therapeutics	Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$213.52M	$2.90B	$4.21B	$11.87B
Dividend Yield	N/A	15.26%	5.61%	5.21%
P/E Ratio	N/A	13.16	23.40	28.47
Price / Sales	N/A	1,690.50	186.69	60.92
Price / Cash	N/A	25.75	52.82	36.52
Price / Book	N/A	3.55	38.31	6.67
Net Income	N/A	-$42.77M	$114.66M	$332.53M
7 Day Performance	-19.36%	1.11%	1.23%	2.01%
1 Month Performance	-36.41%	5.46%	5.54%	9.19%
1 Year Performance	N/A	19.86%	18.68%	39.59%

Polaryx Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PLYX Polaryx Therapeutics	N/A	$4.54 -11.3%	$10.00 +120.3%	N/A	$213.52M	N/A	N/A	11	News Coverage
MRVI Maravai LifeSciences	2.2938 of 5 stars	$3.55 +2.9%	$5.38 +51.4%	N/A	$886.88M	$185.74M	N/A	610	Upcoming Earnings
LBRX LB Pharmaceuticals	N/A	$30.73 -0.1%	$35.25 +14.7%	N/A	$882.47M	N/A	N/A	16
DRUG Bright Minds Biosciences	3.3965 of 5 stars	$89.16 +0.5%	$128.60 +44.2%	N/A	$863.05M	N/A	N/A	N/A
SDGR Schrodinger	2.5451 of 5 stars	$11.79 +3.3%	$20.50 +73.9%	N/A	$842.34M	$255.87M	N/A	790

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PLYX) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Polaryx Therapeutics (PLYX) Competitors

PLYX vs. MRVI, LBRX, DRUG, SDGR, and TBPH

How does Polaryx Therapeutics compare to Maravai LifeSciences?

Summary

How does Polaryx Therapeutics compare to LB Pharmaceuticals?

Summary

How does Polaryx Therapeutics compare to Bright Minds Biosciences?

Summary

How does Polaryx Therapeutics compare to Schrodinger?

Summary

How does Polaryx Therapeutics compare to Theravance Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLYX vs. The Competition

Polaryx Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Polaryx Therapeutics (PLYX) Competitors

PLYX vs. MRVI, LBRX, DRUG, SDGR, and TBPH

How does Polaryx Therapeutics compare to Maravai LifeSciences?

Summary

How does Polaryx Therapeutics compare to LB Pharmaceuticals?

Summary

How does Polaryx Therapeutics compare to Bright Minds Biosciences?

Summary

How does Polaryx Therapeutics compare to Schrodinger?

Summary

How does Polaryx Therapeutics compare to Theravance Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLYX vs. The Competition

Polaryx Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools